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Abstract
Background: Primary hepatic leiomyosarcoma is a rare disease diagnosed in older aged adults with a median age of 
58 and occasionally in children with a history of immunosuppression.
Methods: From 1998 to 2009, 215 patients were diagnosed with primary hepatic malignancies at our institution, 4 of 
which were diagnosed with primary hepatic sarcoma (1.8%). Three cases were primary hepatic leiomyosarcomas (LMS) 
and one case was primary undifferentiated embryonal sarcoma of the liver; median age 30 (range 20-39) years.
Results: One patient is currently 12 months post-resection with no evidence of recurrence. Two patients passed away 
at 19 days and 22 months from small for size liver and tumor recurrence respectively.
Conclusion: We have presented 3 cases of primary hepatic leiomyosarcoma diagnosed at our institution with an 
unusually young age distribution and no evidence of immunosuppression. These cases highlight the diagnostic and 
therapeutic challenges of this rare tumour.
Introduction
Primary liver sarcoma is a rare tumor associated with
rapid growth and poor prognosis. The majority of hepatic
malignancies are carcinomas with sarcomas representing
only 0.1% to 2% of primary hepatic cancers [1]. Present-
ing symptoms are nonspecific and the diagnosis is often
made post-operatively or even post-mortem. Surgery for
resectable tumors combined with adjuvant chemotherapy
is the current standard of care however very little data
exists outside case series due to the rarity of the disease.
Our institution is a leading tertiary referral centre for
the treatment of hepatic malignancies in the region. We
reviewed our cases of primary liver sarcoma and found
three patients presenting with leiomyosarcomas (LMS)
with an unusually young age distribution compared with
previous reports of this disease. We present our cases and
discuss the current literature including controversial
management strategies such as liver transplantation.
Patients
From 1998 to 2009, 215 patients were diagnosed with pri-
mary hepatic malignancies at our institution, 4 of which
were diagnosed with primary hepatic sarcoma (1.8%).
Three cases were primary hepatic leiomyosarcomas
(LMS) and one case was primary undifferentiated embry-
onal sarcoma of the liver; with an age range of 20-39
years.
The first patient was a 25 year old female who pre-
sented with abdominal pain and a palpable right abdomi-
nal mass. A computed tomography (CT) scan revealed a
14 × 10 cm hepatic mass occupying segments 5,6,7,8 and
compressing the right and middle hepatic veins. A right
hepatectomy was subsequently performed. Histopathol-
ogy revealed a primary hepatic leiomyosarcoma; immu-
nohistochemistry showed positive staining for vimentin,
desmin, smooth muscle actin (SMA) and muscle specific
actin (MSA). The surgical margins were negative and the
tumour was classified as stage I sarcoma under the Amer-
i c a n  J o i n t  C o m m i t t e e  o n  C a n c e r  ( A J C C )  c l a s s i f i c a t i o n
system. The patient received adjuvant chemotherapy
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however the tumor recurred with distant metastasis and
she passed away 22 months post resection.
The second patient was a 39 year old male who pre-
sented with abdominal pain associated with anorexia,
fever and weight loss. A palpable abdominal mass was
found on clinical examination. CT scan revealed a 27 × 22
× 17 cm mass in the right hepatic lobe. The lesion showed
multiple internal hypodense areas compatible with
necrosis. Fine needle aspiration was consistent with leio-
myosarcoma. Immunohistochemistry showed positive
staining for actin, desmin, and was strongly positive for
vimentin. An extended right hepatectomy was performed
and histopathological examination revealed a tumor size
of 33 × 23 × 20 cm with positive surgical margins. One
week post surgery, the patient developed fulminant liver
failure secondary to small for size syndrome and passed
away 19 days after surgery.
The third patient was a 30-year old male who presented
with abdominal pain associated with anorexia, weight
loss, nausea and vomiting. A CT scan showed a large
multi-lobulated lesion measuring 18 × 17.8 × 11.8 cm
occupying almost the entire right hepatic lobe (figure 1).
It appeared heterogeneous with cystic and soft tissue
components. The initial diagnosis was of hydatid disease
of the liver. A right hepatectomy was performed and his-
topathological examination defined the tumor as a stage
IV LMS with metastasis to the abdominal wall. Immuno-
histochemistry showed diffusely positive staining for
MSA, weakly positive for vimentin, and strongly and dif-
fusely positive for SMA. Adjuvant chemotherapy was rec-
ommended and the patient continued his treatment at
another institution. He received six cycles of chemother-
apy and 30 sessions of radiotherapy. The patient is cur-
rently 12 months post-resection with no evidence of
recurrence.
Discussion
Leiomyosarcoma is a malignant mesenchymal tumour of
myogenic origin rarely arising in the liver. Hepatic LMS
has been reported to arise in children in association with
acquired immunodeficiency syndrome (AIDS) and
Epstein-Barr virus (EBV) [2,3]. We have reviewed the
cases of hepatic LMS arising in adults reported in the
English-language literature (Table 1) [4-14]. These show a
median age of 58 with one case occurring in a patient
immunosupressed following renal transplant and two
cases occurring in patients previously treated for Hodg-
kin's lymphoma. The three cases of hepatic LMS diag-
nosed at out institution show an unusually young age
distribution with a median age of 30 (range 25 to 30
years) and no history of immunosuppression or predis-
posing factors.
Matthaei et al reported that survival in most patients
with primary sarcoma of the liver is poor. However a
long-term survival for more than 10 years after curative
surgery (R0 resection) is possible [1]. One of our patients
died soon after resection as a result of liver failure, one
patient died 22 months after resection with metastatic
disease and one patient remains free of disease 12 moths
post-resection.
Diagnosis of hepatic LMS is challenging due to the
non-specific nature of symptoms and lack of serological
markers. Pre-operative histological diagnosis of liver
tumors, particularly hepatocellular carcinomas is contro-
versial due to the risk of needle-track seeding. Only one
of our three patients had a pre-operative diagnosis of
LMS made by FNA. Hepatocellular carcinoma (HCC) is
the commonest primary live tumour and many patients
who are diagnosed with hepatic sarcoma are initially
treated for presumed HCC. In one of our cases the initial
diagnosis was of hydatid disease of the liver which is the
commonest cause of cystic liver lesions in this age group
in our region.
The characteristics of hepatic LMS on CT or magnetic
resonance imaging (MRI) are non-specific. CT imaging
will invariably show a well-defined hypodense mass with
peripheral enhancement with evidence of central necro-
sis or in some cases a cystic appearance. MRI may show
homogeneous hypointensity on T-1 weighted images and
heterogeneous hyperintensity on T-2 weighted images
[15].
Histological examination of LMS reveals a tumour
composed of intersecting bundles of spindle-shaped cells.
Immunohistochemistry will show positivity for desmin, Figure 1 CT scan of patient number 3 with primary hepatic sarco-
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vimentin and smooth muscle actin but negative for kera-
tin, S-100 protein and neuron-specific enolase.
The standard treatment for liver sarcomas is surgical
resection followed by adjuvant chemotherapy however
due to the rarity of the disease, there is very little data
regarding optimal management and this remains empiri-
cal.
The efficacy of chemotherapy for LMS in general is
unclear, particularly since older series include chemo-
resistant gastrointestinal stromal tumors (GISTs) that are
now treated with the c-kit inhibitor imatinib. The cyto-
toxic agents doxorubicin and ifosfamide are commonly
used for many subtypes of soft tissue sarcoma both in the
adjuvant and palliative setting. In a retrospective study of
first-line chemotherapy for unresectable or metastatic
LMS from different primary sites the overall response
rate was 18%; median progression-free survival and over-
all survival were 3.8 months and 9.7 months respectively
[16]. There is evidence that the combination of gemcit-
abine and docetaxel is active in uterine LMS with some
evidence that it may be beneficial in the adjuvant setting
[17]. The evidence of gemcitabine and docetaxel in
advanced non-uterine LMS is less compelling and there
are no studies evaluating adjuvant therapy non-uterine
LMS.
Complete resection of the primary tumour (R0 status)
is only potentially curative treatment for primary liver
sarcoma. The largest case series of 22 primary hepatic
sarcomas reported by Matthei et al found that no patient
survived longer than 3 years after incomplete tumour
resection [1].
Liver transplantation for primary hepatic sarcoma is
controversial. Orthotopic liver transplantation (OLT) is
now accepted as a valuable therapeutic option for early,
unresectable HCC. Initial results showed high levels of
tumour recurrence and disappointing short and long
term survival rates however the seminal study by Mazzaf-
erro et al in 1996 culminating in the development of the
"Milan Criteria" established OLT as a viable treatment for
HCC. These criteria stipulated that patients with a single
Table 1: Previous English-language reports of primary hepatic leiomyosarcoma in adults
Authors Gender Age Past medical history Follow-up
Liang 2009 [11] F 44 Hepatitis B Died 34 months
Giuliante 2009 [12] M 26 Hodgkin's Lymphoma Died 25 months
Matthei 2009 [1] F 19 Died 73 months
F 64 NED 181 months
F 53 Died 21 months
M 55 NED 133 months
M 51 NED 144 months
M 59 Died 45 months
F 63 NED 133 months
Watanabe 2008 [13] M 63 PMD
F4 9 P M D
Almogy 2004 [14] F 58 Died 4 months
F 63 Died 12 months
Fujita 2002 [15] F 33 Prior renal transplant NED 24 months
Iordanidis 2002 [16] M 35 Died 3 months
Tsuji 2002 [17] M 68 Hepatitis C PMD
Soyer 1996 [7] F 67
Sato 2000 [18] F 62 PMD
Holloway 1996 [19] M 63
Ferrozi 1996 [4] M 50
F 35 Hodgkin's Lymphoma NED 6 months
Baur 1993 [20] F 69 Recurrence 10 years 
post-resection
Paraskevopoulos 1991 [21] M 62 NED 5 months
NED: No evidence of disease, PMD: Post mortem diagnosisShamseddine et al. World Journal of Surgical Oncology 2010, 8:56
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tumour less than 5 cm or up to three tumors with the
largest less than 3 cm with no evidence of vascular inva-
sion, nodal or distant metastasis could be transplanted
with acceptable rates of recurrence and overall survival
comparable to OLT for benign disease. Transplantation
for HCC within the Milan Criteria can achieve 4-year
survival rates of 85% to 92% [18].
Liver transplantation for primary hepatic sarcoma has
not been as successful as OLT for HCC. Due to concerns
regarding needle-track seeding, most patients do not
have a pre-operative histological diagnosis and the diag-
nosis of sarcoma is made on histological examination of
the explanted liver. Husted et al reported the outcomes
for 19 patients identified as undergoing OLT for primary
or metastatic liver sarcoma. The 6 patients transplanted
for primary hepatic sarcoma had primary hepatic
angiosarcoma and had recurrence of disease at a median
interval of 2 months (range 2 -10 months). Median sur-
vival was 5.7 months after transplantation (range 2.6-15.4
months) with all patients dying of disease recurrence. For
the 13 patients receiving OLT for metastatic sarcoma to
the liver, all patients had prior control of their primary
malignancy before consideration of OLT and were free of
extra-hepatic disease at the time of transplantation.
Twelve patients had recurrence of disease after a median
of 11.7 months (range 2-90 months), ten patients died of
recurrent disease. The three long-term survivors have
what is now termed GIST and are maintained on imatinib
[19].
There are four reported cases of OLT for primary
hepatic LMS. Saint-Paul et al. reported a case of primary
hepatic LMS diagnosed post-transplant for presumed
HCC who died 15 days post-operatively [20]. In the case
series reported my Matthaei et al; two patients with
hepatic LMS underwent OLT. A 19 year-old female with a
6 cm grade 2 hepatic LMS underwent OLT however
developed diffuse pulmonary metastasis and died 73
months post-transplant. The second patient with hepatic
LMS, a 52 year-old male, underwent OLT for two grade 2
lesions measuring 4 cm and 5 cm. He had local chest wall
recurrence resected and was alive with no evidence of
disease at 141 months [1]. The final reported case of OLT
for hepatic LMS was a 44 year-old female with a pre-
sumed HCC on a background of hepatitis B measuring 5
cm. Histological examination of the explanted liver
revealed hepatic LMS. Fourteen months post-transplant
the patients developed recurrent disease metastatic to
axillary lymph nodes. The immunosuppressive regimen
was changed from tacrolimus to sirolimus and the patient
survived for an additional 20 months before dying of
extensive metastatic disease [21]. The interplay between
immunosuppression and the development and progres-
sion of LMS is poorly understood however this case dem-
onstrates the importance of immune status manipulation
as a therapeutic strategy. Smooth muscle tumors are
being increasingly recognized in immunodeficient chil-
dren. One case EBV-related hepatic LMS arising post-
liver transplant in a 2 year-old child responded to taper-
ing of immunosuppression with the child remaining
symptom-free with stable disease for 12 years [3].
Conclusion
We have presented 3 cases of primary hepatic leiomyo-
sarcoma diagnosed at our institution with an unusually
young age distribution and no evidence of immunosup-
pression. These cases highlight the diagnostic and thera-
peutic challenges of this rare tumour. We have reviewed
the literature and discussed treatment strategies includ-
ing adjuvant chemotherapy and liver transplantation.
Curative resection is the mainstay of treatment for
hepatic leiomyosarcoma. In cases primary liver tumors
with unusual features we would advocate pre-operative
histological diagnosis in order to optimize management.
Liver transplantation for hepatic LMS cannot be recom-
mended due to high rates of tumour recurrence however
in cases of LMS diagnosed on histopatholgical examina-
tion of the explanted liver or LMS arising post-transplant
associated with immunosuppression, immune system
modulation is an important strategy to consider. The role
of adjuvant chemotherapy for hepatic LMS is unclear and
remains empirical. In view of treatment advances in the
treatment of uterine LMS, patients with non-uterine
LMS should be offered treatment within clinical trials
whenever possible to improve our understanding of this
rare disease and improve outcomes for patients.
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